Your browser doesn't support javascript.
loading
Transformer-based AI technology improves early ovarian cancer diagnosis using cfDNA methylation markers.
Li, Gen; Zhang, Yongqiang; Li, Kun; Liu, Xiaohong; Lu, Yaping; Zhang, Zhenlin; Liu, Zhihai; Wu, Yong; Liu, Fei; Huang, Hong; Yu, Meixing; Yang, Zhao; Zheng, Xiaoxue; Guo, Chengbin; Gao, Yuanxu; Wang, Taorui; Fok, Manson; Yiu-Nam Lau, Johnson; Shi, Kun; Gu, Xiaoqiong; Guo, Lingchuan; Luo, Huiyan; Zeng, Fanxin; Zhang, Kang.
Afiliación
  • Li G; Guangzhou Women and Children's Medical Center, Guangzhou, China. Electronic address: superleegen@hotmail.com.
  • Zhang Y; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Li K; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Liu X; Zhuhai International Eye Center and Precision Medicine Center, Zhuhai People's Hospital and The First Affiliated Hospital of Faculty of Medicine, Macau University of Technology, Zhuhai, China; Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Big Data, Wenzhou Eye Hospi
  • Lu Y; Sinopharm Medical Laboratory (Wuhan), Sinopharm (Wuhan) Precision Medical Technology, Sinopharm Genomics Technology Co., Ltd., Wuhan 430030, China.
  • Zhang Z; Zhuhai International Eye Center and Precision Medicine Center, Zhuhai People's Hospital and The First Affiliated Hospital of Faculty of Medicine, Macau University of Technology, Zhuhai, China.
  • Liu Z; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Wu Y; Guangzhou Overseas Chinese Hospital, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Liu F; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Huang H; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Yu M; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Yang Z; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Zheng X; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Guo C; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Gao Y; Zhuhai International Eye Center and Precision Medicine Center, Zhuhai People's Hospital and The First Affiliated Hospital of Faculty of Medicine, Macau University of Technology, Zhuhai, China; Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Big Data, Wenzhou Eye Hospi
  • Wang T; Zhuhai International Eye Center and Precision Medicine Center, Zhuhai People's Hospital and The First Affiliated Hospital of Faculty of Medicine, Macau University of Technology, Zhuhai, China.
  • Fok M; Zhuhai International Eye Center and Precision Medicine Center, Zhuhai People's Hospital and The First Affiliated Hospital of Faculty of Medicine, Macau University of Technology, Zhuhai, China.
  • Yiu-Nam Lau J; Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong.
  • Shi K; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Gu X; Guangzhou Women and Children's Medical Center, Guangzhou, China.
  • Guo L; Department of Pathology, The First Affiliated Hospital of Suzhou University, Suzhou, China. Electronic address: szglc@hotmail.com.
  • Luo H; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address: luoucsd@126.com.
  • Zeng F; Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China. Electronic address: zengfx@pku.edu.cn.
  • Zhang K; Zhuhai International Eye Center and Precision Medicine Center, Zhuhai People's Hospital and The First Affiliated Hospital of Faculty of Medicine, Macau University of Technology, Zhuhai, China; Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Big Data, Wenzhou Eye Hospi
Cell Rep Med ; 5(8): 101666, 2024 Aug 20.
Article en En | MEDLINE | ID: mdl-39094578
ABSTRACT
Epithelial ovarian cancer (EOC) is the deadliest women's cancer and has a poor prognosis. Early detection is the key for improving survival (a 5-year survival rate in stage I/II is over 70% compared to that of 25% in stage III/IV) and can be achieved through methylation markers from circulating cell-free DNA (cfDNA) using a liquid biopsy. In this study, we first identify top 500 EOC markers differentiating EOC from healthy female controls from 3.3 million methylome-wide CpG sites and validated them in 1,800 independent cfDNA samples. We then utilize a pretrained AI transformer system called MethylBERT to develop an EOC diagnostic model which achieves 80% sensitivity and 95% specificity in early-stage EOC diagnosis. We next develop a simple digital droplet PCR (ddPCR) assay which archives good performance, facilitating early EOC detection.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Biomarcadores de Tumor / Metilación de ADN / Detección Precoz del Cáncer / Ácidos Nucleicos Libres de Células Límite: Female / Humans / Middle aged Idioma: En Revista: Cell Rep Med Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Biomarcadores de Tumor / Metilación de ADN / Detección Precoz del Cáncer / Ácidos Nucleicos Libres de Células Límite: Female / Humans / Middle aged Idioma: En Revista: Cell Rep Med Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos